MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced the positive results of OB-202, a 28-week, phase 2 clinical trial in type 2 diabetics. Subjects treated with Qnexa had a reduction in HbA1c, a common measure of glycemic control, of 1.2 percent, from 8.7 percent to 7.5 percent, as compared with a reduction of 0.6 percent, from 8.6 percent to 8.0 percent, in subjects in the placebo group (p<0.001). Subjects treated with Qnexa also lost 8.0 percent of their baseline body weight, or 7.7 kg, as compared to 1.2 percent weight loss, or 1.3 kg, observed in the placebo group (p<0.001). Fasting plasma glucose levels were reduced in the Qnexa arm from 174.7 mg/dL to 141.9 mg/dL, and decreased from 174 mg/dL to 166.6 mg/dL in the placebo group (p<0.001). Qnexa patients also had significant improvement in cardiovascular risk factors including blood pressure, triglycerides levels and waist circumference. The trial randomized 206 subjects at 10 sites. The Qnexa treatment group had a study completion rate of 85 percent, as compared to 72 percent in the placebo arm. Qnexa subjects reported an overall improvement when evaluated for quality of life, including physical function, self-esteem and distress.
